RxDoctor Payments Data

Ali Bazzi, MD

Cardiovascular Disease · Aventura, FLNPI 1477553063

Payments from drug & device makers

$25,050in general payments, 2019–2025

Across 355 payments — averaging $70.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$10K
  • Medtronic$7K
  • Boston Scientific$3K
  • Johnson & Johnson$726
  • Pfizer$710
  • Abbott$432
  • plus $4K from 35 others

What the payments were for

  • Speaking & faculty fees$9,00136%
  • Travel & lodging$6263%
  • Food & beverage$15,17861%
  • Education$2451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,050 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$132,071
Medicare patients
901
Services billed
2,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban232$271,680
EntrestoSacubitril/Valsartan189$250,254
XareltoRivaroxaban193$205,177
Repatha SureclickEvolocumab151$130,330
FarxigaDapagliflozin Propanediol102$104,219
BrilintaTicagrelor42$47,349
JardianceEmpagliflozin20$27,222
MultaqDronedarone Hcl16$16,273
Repatha SyringeEvolocumab13$13,763
VascepaIcosapent Ethyl18$12,762
Ranolazine ErRanolazine98$10,498
Rosuvastatin Calcium423$4,888
Metoprolol Succinate441$4,345
Atorvastatin Calcium429$3,641
Nifedipine ErNifedipine139$3,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$710$271,680232 claims
NovartisEntresto$267$250,254189 claims
Johnson & JohnsonXarelto$726$205,177193 claims
AstraZenecaFarxiga, Brilinta$291$151,568144 claims
Boehringer IngelheimJardiance$302$27,22220 claims
Sanofi-aventis U.S. LLCMultaq$161$16,27316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Aventura

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →